Your browser doesn't support javascript.
loading
[Neurological Complications with Paraplegia as Main Manifestation after Hematopoietic Stem Cell Transplantation].
Xue, Song; Zhang, Yong-Ping; Zhang, Shu-Qin; Xiao, Tian-Yi; Xu, Yi-Cheng; Cui, Bin; Wang, Jing-Bo.
Afiliación
  • Xue S; Department of Hematology, Aerospace Center Hospital，Beijing 100049, China.
  • Zhang YP; Department of Hematology, Aerospace Center Hospital，Beijing 100049, China.
  • Zhang SQ; Department of Hematology, Aerospace Center Hospital，Beijing 100049, China.
  • Xiao TY; Department of Neurology, Aerospace Center Hospital，Beijing 100049, China.
  • Xu YC; Department of Neurology, Aerospace Center Hospital，Beijing 100049, China.
  • Cui B; Department of Radiology, Aerospace Center Hospital，Beijing 100049, China,E-mail: cuibin@asch.net.cn.
  • Wang JB; Department of Hematology, Aerospace Center Hospital，Beijing 100049, China,E-mail: wangjingbo@asch.net.cn.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 28(2): 595-601, 2020 Apr.
Article en Zh | MEDLINE | ID: mdl-32319402
OBJECTIVE: To investigate the cause, diagnosis and therapeutic method of the neurological complication with the main manifestation of paraplegia after the hematopoietic stem cell transplantation (HSCT). METHODS: The clinical features, the process of diagnosis and treatment and the prognosis follow-up of 9 cases, who received HSCT in our department during January 2014 and January 2017 and had the neurological complication with the main symptom of paraplegia after the transplantation, were summarized. RESULTS: The incidence rate of paraplegia was 2.96% (9/304). The median onset time was 245 days (50 days-772 days) after transplantation. The cause of paraplegia determined by examination was extramedullary recurrence of leukemia in 3 cases, cyclosporin neurotoxicity in 1 case, GBS in 1 case, CIDP in 2 cases and autoimmune myeleterosis in 2 cases. One patient abandoned the treatment. The rest 8 patients received empirical or targeted treatment. The median follow-up period was 11 months. There were 5 dead cases and 4 survival cases. CONCLUSION: Paraplegia is a serious post-HSCT complication. The cause of paraplegia should be determined as early as possible to perform targeted treatment. Empirical preemptive treatment should be given if necessary, so as to improve the survival rate and the quality of life of HSCT patients.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Paraplejía / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Observational_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Humans Idioma: Zh Revista: Zhongguo Shi Yan Xue Ye Xue Za Zhi Asunto de la revista: HEMATOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: China Pais de publicación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Paraplejía / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Observational_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Humans Idioma: Zh Revista: Zhongguo Shi Yan Xue Ye Xue Za Zhi Asunto de la revista: HEMATOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: China Pais de publicación: China